Soft Mist Inhalers: Lung Deposition Benefits For Respiratory Conditions

Biopharma companies face growing demand to address acute respiratory conditions, with the global inhalation drug delivery market projected to reach $20.7 billion by 2031, growing at a 4.4% CAGR. Inhalation therapies offer direct delivery to target sites, rapid onset, and reduced systemic side effects compared to oral treatments, driving remarkable market growth. Soft Mist Inhalers (SMIs) are expected to grow even faster, at a 6.8% CAGR, surpassing £4.4 billion by 2031, offering opportunities for customization, personalized dosing, improved adherence, and long-term cost-effectiveness.

This expanding market encourages drug developers to reformulate non-inhaled molecules for pulmonary delivery, as demonstrated by the conversion of intravenous dihydroergotamine into the breath-actuated Tempo MDI for migraine treatment. This guide examines inhalation device types, highlighting the increasing role of SMIs and their impact on early formulation development and enhanced lung deposition.

Explore how optimizing inhalation device selection can unlock the full potential of pulmonary drug delivery for next-generation therapies.